Contribution of L-alanine dehydrogenase to in vivo persistence and protective efficacy of the BCG vaccine

Microbiology and Immunology

Volumn 50, Issue 10, 2006, Pages 805-810

  Scandurra, Gabriella M ^a,c   Ryan, Anthony A ^a   Pinto, Rachel ^a,d   Britton, Warwick J ^a,b   Triccas, James A ^a,b  

^a CENTENARY INSTITUTE   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c AGRESEARCH   (New Zealand)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Alanine dehydrogenase; BCG vaccine; Tuberculosis; Virulence

Indexed keywords

ALANINE DEHYDROGENASE; BCG VACCINE;

AEROSOL; ARTICLE; BACTERIAL GROWTH; DRUG EFFICACY; GENETIC CODE; IN VIVO STUDY; LUNG TUBERCULOSIS; MACROPHAGE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PROTECTION; PROTEIN DEGRADATION;

MYCOBACTERIUM BOVIS BCG; MYCOBACTERIUM TUBERCULOSIS;

EID: 33750286565     PISSN: 03855600     EISSN: 13480421     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2006.tb03856.x     Document Type: Article

References (25)

1. Andersen, A.B., Andersen, P., and Ljungqvist, L. 1992. Structure and function of a 40,000-molecular-weight protein antigen of Mycobacterium tuberculosis. Infect. Immun. 60: 2317-2323.
2. Behr, M.A., Wilson, M.A., Gill, W.P., Salomon, H., Schoolnik, G.K., Rane, S., and Small, P.M. 1999. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 284: 1520-1523.
3. Belley, A., Alexander, D., Di Pietrantonio, T., Girard, M., Jones, J., Schurr, E., Liu, J., Sherman, D.R., and Behr, M.A. 2004. Impact of methoxymycolic acid production by Mycobacterium bovis BCG vaccines. Infect. Immun. 72: 2803-2809.
4. Betts, J.C., Lukey, P.T., Robb, L.C., McAdam, R.A., and Duncan, K. 2002. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol. Microbiol. 43: 717-731.
5. Chan, K., Knaak, T., Satkamp, L., Humbert, O., Falkow, S., and Ramakrishnan, L. 2002. Complex pattern of Mycobacterium marinum gene expression during long-term granulomatous infection. Proc. Natl. Acad. Sci. U.S.A. 99: 3920-3925.
6. Chen, J.M., Alexander, D.C., Behr, M.A., and Liu, J. 2003. Mycobacterium bovis BCG vaccines exhibit defects in alanine and serine catabolism. Infect. Immun. 71: 708-716.
7. +- cytotoxic-T-cell responses to novel epitopes in Mycobacterium tuberculosis superoxide dismutase, alanine dehydrogenase, and glutamine synthetase. Infect. Immun. 72: 2412-2415.
8. Fine, P.E. 1995. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346: 1339-1345.
9. Garnier, T., Eiglmeier, K., Camus, J.C., Medina, N., Mansoor, H., Pryor, M., Duthoy, S., Grondin, S., Lacroix, C., Monsempe, C., Simon, S., Harris, B., Atkin, R., Doggett, J., Mayes, R., Keating, L., Wheeler, P.R., Parkhill, J., Barrell, B.G., Cole, S.T., Gordon, S.V., and Hewinson, R.G. 2003. The complete genome sequence of Mycobacterium bovis. Proc. Natl. Acad. Sci. U.S.A. 100: 7877-7882.
10. Gomez, J.E., and McKinney, J.D. 2004. Mycobacterium tuberculosis persistence, latency, and drug tolerance. Tuberculosis 84: 29-44.
11. Horwitz, M.A., Harth, G., Dillon, B.J., and Maslesa-Galic, S. 2000. Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc. Natl. Acad. Sci. U.S.A. 97: 13853-13858.
12. Jungblut, P.R., Schaible, U.E., Mollenkopf, H.J., Zimny-Arndt, U., Raupach, B., Mattow, J., Halada, P., Lamer, S., Hagens, K., and Kaufmann, S.H. 1999. Comparative proteome analysis of Mycobacterium tuberculosis and Mycobacterium bovis BCG strains: towards functional genomics of microbial pathogens. Mol. Microbiol. 33: 1103-1117.
13. Kamath, A.T., Feng, C.G., Macdonald, M., Briscoe, H., and Britton, W.J. 1999. Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis. Infect. Immun. 67: 1702-1707.
14. Mahairas, G.G., Sabo, P.J., Hickey, M.J., Singh, D.C., and Stover, C.K. 1996. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J. Bacteriol. 178: 1274-1282.
15. Mollenkopf, H.J., Grode, L., Mattow, J., Stein, M., Mann, P., Knapp, B., Ulmer, J., and Kaufmann, S.H. 2004. Application of mycobacterial proteomics to vaccine design: improved protection by Mycobacterium bovis BCG prime-Rv3407 DNA boost vaccination against tuberculosis. Infect. Immun. 72: 6471-6479.
16. Palendira, U., Spratt, J.M., Britton, W.J., and Triccas, J.A. 2005. Expanding the antigenic repertoire of BCG improves protective efficacy against aerosol Mycobacterium tuberculosis infection. Vaccine 23: 1680-1685.
17. Pelicic, V., Jackson, M., Reyrat, J.M., Jacobs, W.R., Jr., Gicquel, B., and Guilhot, C. 1997. Efficient allelic exchange and transposon mutagenesis in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U.S.A. 94: 10955-10960.
18. Pinto, R., Saunders, B.M., Camacho, L.R., Britton, W.J., Gicquel, B., and Triccas, J.A. 2004. Mycobacterium tuberculosis defective in phthiocerol dimycocerosate translocation provides greater protective immunity against tuberculosis than the existing bacille Calmette-Guerin vaccine. J. Infect. Dis. 189: 105-112.
19. Pym, A.S., Brodin, P., Brosch, R., Huerre, M., and Cole, S.T. 2002. Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti. Mol. Microbiol. 46: 709-717.
20. Pym, A.S., Brodin, P., Majlessi, L., Brosch, R., Demangel, C., Williams, A., Griffiths, K.E., Marchai, G., Leclerc, C., and Cole, S.T. 2003. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat. Med. 9: 533-539.
21. Raynaud, C., Etienne, G., Peyron, P., Laneelle, M.A., and Daffe, M. 1998. Extracellular enzyme activities potentially involved in the pathogenicity of Mycobacterium tuberculosis. Microbiology 144: 577-587.
22. Reed, M.B., Domenech, P., Manca, C., Su, H., Barczak, A.K., Kreiswirth, B.N., Kaplan, G., and Barry, C.E., 3rd. 2004. A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response. Nature 431: 84-87.
23. Rosenkrands, I., Slayden, R.A., Crawford, J., Aagaard, C., Barry, C.E., 3rd, and Andersen, P. 2002. Hypoxic response of Mycobacterium tuberculosis studied by metabolic labeling and proteome analysis of cellular and extracellular proteins. J. Bacteriol. 184: 3485-3491.
24. Spratt, J.M., Ryan, A.A., Britton, W.J., and Triccas, J.A. 2005. Epitope-tagging vectors for the expression and detection of recombinant proteins in mycobacteria. Plasmid 53: 269-273.
25. Spreadbury, C.L., Pallen, M.J., Overton, T., Behr, M.A., Mostowy, S., Spiro, S., Busby, S.J., and Cole, J.A. 2005. Point mutations in the DNA- and cNMP-binding domains of the homologue of the cAMP receptor protein (CRP) in Mycobacterium bovis BCG: implications for the inactivation of a global regulator and strain attenuation. Microbiology 151: 547-556.